-
Sector Analysis
Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease that causes progressive fibrosis of the skin and internal organs, as well as vascular dysfunction. The presentation of the disease is heterogeneous, both in the organ systems affected and the overall severity of symptoms. The most common complications of SSc include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, lung fibrosis or interstitial lung disease (ILD), pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. As there are...
-
Thematic Analysis
Microbiome-Targeted Therapeutics in Immunology
Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.
-
Sector Analysis
PharmaPoint: Crohn’s Disease – Global Drug Forecast and Market Analysis to 2026
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized...
-
Sector Analysis
Competitor Landscape: Psoriasis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Psoriasis (PsO) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Digital Landscape: Psoriasis
The Digital Landscape Psoriasis report analyzes digital activities undertaken by pharma in support of therapies for moderate-to-severe psoriasis (PsO).
-
Consumer Insights
KOL Perspectives: Novel treatment options for moderate UC
› This KOL Insight briefing focuses on KOLs views of novel treatment options for moderate UC
-
Sector Analysis
PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025
Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men...
-
Sector Analysis
Psoriasis – 5EU Drug Forecast and Market Analysis to 2024
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients. GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising...
-
Sector Analysis
PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients. GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising...
-
Sector Analysis
Psoriasis – US Drug Forecast and Market Analysis to 2024
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients. GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising...